Global Drugs for HIV Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
HIV/AIDS is one of the most serious chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease.
LPI (LP Information)' newest research report, the “Drugs for HIV Industry Forecast” looks at past sales and reviews total world Drugs for HIV sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for HIV sales for 2023 through 2029. With Drugs for HIV sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for HIV industry.
This Insight Report provides a comprehensive analysis of the global Drugs for HIV landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for HIV portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Drugs for HIV market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for HIV and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for HIV.
The global Drugs for HIV market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Drugs for HIV is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Drugs for HIV is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Drugs for HIV is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Drugs for HIV players cover ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp & Dohme Corp, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Mylan Pharmaceuticals Inc., Genentech, Inc. and AbbVie Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for HIV market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Drugs for HIV market?
What factors are driving Drugs for HIV market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drugs for HIV market opportunities vary by end market size?
How does Drugs for HIV break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
HIV/AIDS is one of the most serious chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease.
LPI (LP Information)' newest research report, the “Drugs for HIV Industry Forecast” looks at past sales and reviews total world Drugs for HIV sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for HIV sales for 2023 through 2029. With Drugs for HIV sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for HIV industry.
This Insight Report provides a comprehensive analysis of the global Drugs for HIV landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for HIV portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Drugs for HIV market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for HIV and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for HIV.
The global Drugs for HIV market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Drugs for HIV is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Drugs for HIV is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Drugs for HIV is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Drugs for HIV players cover ViiV Healthcare, Gilead Sciences, Inc, Merck Sharp & Dohme Corp, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Mylan Pharmaceuticals Inc., Genentech, Inc. and AbbVie Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for HIV market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Integrase Inhibitors
- Combination HIV Medicines
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ViiV Healthcare
- Gilead Sciences, Inc
- Merck Sharp & Dohme Corp
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Mylan Pharmaceuticals Inc.
- Genentech, Inc.
- AbbVie Inc.
What is the 10-year outlook for the global Drugs for HIV market?
What factors are driving Drugs for HIV market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drugs for HIV market opportunities vary by end market size?
How does Drugs for HIV break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Drugs for HIV Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Drugs for HIV by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Drugs for HIV by Country/Region, 2018, 2022 & 2029
2.2 Drugs for HIV Segment by Type
2.2.1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.2.2 Integrase Inhibitors
2.2.3 Combination HIV Medicines
2.2.4 Others
2.3 Drugs for HIV Sales by Type
2.3.1 Global Drugs for HIV Sales Market Share by Type (2018-2023)
2.3.2 Global Drugs for HIV Revenue and Market Share by Type (2018-2023)
2.3.3 Global Drugs for HIV Sale Price by Type (2018-2023)
2.4 Drugs for HIV Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.4.4 Others
2.5 Drugs for HIV Sales by Application
2.5.1 Global Drugs for HIV Sale Market Share by Application (2018-2023)
2.5.2 Global Drugs for HIV Revenue and Market Share by Application (2018-2023)
2.5.3 Global Drugs for HIV Sale Price by Application (2018-2023)
3 GLOBAL DRUGS FOR HIV BY COMPANY
3.1 Global Drugs for HIV Breakdown Data by Company
3.1.1 Global Drugs for HIV Annual Sales by Company (2018-2023)
3.1.2 Global Drugs for HIV Sales Market Share by Company (2018-2023)
3.2 Global Drugs for HIV Annual Revenue by Company (2018-2023)
3.2.1 Global Drugs for HIV Revenue by Company (2018-2023)
3.2.2 Global Drugs for HIV Revenue Market Share by Company (2018-2023)
3.3 Global Drugs for HIV Sale Price by Company
3.4 Key Manufacturers Drugs for HIV Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drugs for HIV Product Location Distribution
3.4.2 Players Drugs for HIV Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DRUGS FOR HIV BY GEOGRAPHIC REGION
4.1 World Historic Drugs for HIV Market Size by Geographic Region (2018-2023)
4.1.1 Global Drugs for HIV Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Drugs for HIV Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Drugs for HIV Market Size by Country/Region (2018-2023)
4.2.1 Global Drugs for HIV Annual Sales by Country/Region (2018-2023)
4.2.2 Global Drugs for HIV Annual Revenue by Country/Region (2018-2023)
4.3 Americas Drugs for HIV Sales Growth
4.4 APAC Drugs for HIV Sales Growth
4.5 Europe Drugs for HIV Sales Growth
4.6 Middle East & Africa Drugs for HIV Sales Growth
5 AMERICAS
5.1 Americas Drugs for HIV Sales by Country
5.1.1 Americas Drugs for HIV Sales by Country (2018-2023)
5.1.2 Americas Drugs for HIV Revenue by Country (2018-2023)
5.2 Americas Drugs for HIV Sales by Type
5.3 Americas Drugs for HIV Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for HIV Sales by Region
6.1.1 APAC Drugs for HIV Sales by Region (2018-2023)
6.1.2 APAC Drugs for HIV Revenue by Region (2018-2023)
6.2 APAC Drugs for HIV Sales by Type
6.3 APAC Drugs for HIV Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Drugs for HIV by Country
7.1.1 Europe Drugs for HIV Sales by Country (2018-2023)
7.1.2 Europe Drugs for HIV Revenue by Country (2018-2023)
7.2 Europe Drugs for HIV Sales by Type
7.3 Europe Drugs for HIV Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Drugs for HIV by Country
8.1.1 Middle East & Africa Drugs for HIV Sales by Country (2018-2023)
8.1.2 Middle East & Africa Drugs for HIV Revenue by Country (2018-2023)
8.2 Middle East & Africa Drugs for HIV Sales by Type
8.3 Middle East & Africa Drugs for HIV Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drugs for HIV
10.3 Manufacturing Process Analysis of Drugs for HIV
10.4 Industry Chain Structure of Drugs for HIV
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drugs for HIV Distributors
11.3 Drugs for HIV Customer
12 WORLD FORECAST REVIEW FOR DRUGS FOR HIV BY GEOGRAPHIC REGION
12.1 Global Drugs for HIV Market Size Forecast by Region
12.1.1 Global Drugs for HIV Forecast by Region (2024-2029)
12.1.2 Global Drugs for HIV Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Drugs for HIV Forecast by Type
12.7 Global Drugs for HIV Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Drugs for HIV Product Portfolios and Specifications
13.1.3 ViiV Healthcare Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Gilead Sciences, Inc
13.2.1 Gilead Sciences, Inc Company Information
13.2.2 Gilead Sciences, Inc Drugs for HIV Product Portfolios and Specifications
13.2.3 Gilead Sciences, Inc Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Gilead Sciences, Inc Main Business Overview
13.2.5 Gilead Sciences, Inc Latest Developments
13.3 Merck Sharp & Dohme Corp
13.3.1 Merck Sharp & Dohme Corp Company Information
13.3.2 Merck Sharp & Dohme Corp Drugs for HIV Product Portfolios and Specifications
13.3.3 Merck Sharp & Dohme Corp Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Sharp & Dohme Corp Main Business Overview
13.3.5 Merck Sharp & Dohme Corp Latest Developments
13.4 Bristol-Myers Squibb Company
13.4.1 Bristol-Myers Squibb Company Company Information
13.4.2 Bristol-Myers Squibb Company Drugs for HIV Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Company Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bristol-Myers Squibb Company Main Business Overview
13.4.5 Bristol-Myers Squibb Company Latest Developments
13.5 Janssen Pharmaceuticals, Inc.
13.5.1 Janssen Pharmaceuticals, Inc. Company Information
13.5.2 Janssen Pharmaceuticals, Inc. Drugs for HIV Product Portfolios and Specifications
13.5.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Janssen Pharmaceuticals, Inc. Main Business Overview
13.5.5 Janssen Pharmaceuticals, Inc. Latest Developments
13.6 Theratechnologies Inc.
13.6.1 Theratechnologies Inc. Company Information
13.6.2 Theratechnologies Inc. Drugs for HIV Product Portfolios and Specifications
13.6.3 Theratechnologies Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Theratechnologies Inc. Main Business Overview
13.6.5 Theratechnologies Inc. Latest Developments
13.7 Mylan Pharmaceuticals Inc.
13.7.1 Mylan Pharmaceuticals Inc. Company Information
13.7.2 Mylan Pharmaceuticals Inc. Drugs for HIV Product Portfolios and Specifications
13.7.3 Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Mylan Pharmaceuticals Inc. Main Business Overview
13.7.5 Mylan Pharmaceuticals Inc. Latest Developments
13.8 Genentech, Inc.
13.8.1 Genentech, Inc. Company Information
13.8.2 Genentech, Inc. Drugs for HIV Product Portfolios and Specifications
13.8.3 Genentech, Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Genentech, Inc. Main Business Overview
13.8.5 Genentech, Inc. Latest Developments
13.9 AbbVie Inc.
13.9.1 AbbVie Inc. Company Information
13.9.2 AbbVie Inc. Drugs for HIV Product Portfolios and Specifications
13.9.3 AbbVie Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AbbVie Inc. Main Business Overview
13.9.5 AbbVie Inc. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Drugs for HIV Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Drugs for HIV by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Drugs for HIV by Country/Region, 2018, 2022 & 2029
2.2 Drugs for HIV Segment by Type
2.2.1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.2.2 Integrase Inhibitors
2.2.3 Combination HIV Medicines
2.2.4 Others
2.3 Drugs for HIV Sales by Type
2.3.1 Global Drugs for HIV Sales Market Share by Type (2018-2023)
2.3.2 Global Drugs for HIV Revenue and Market Share by Type (2018-2023)
2.3.3 Global Drugs for HIV Sale Price by Type (2018-2023)
2.4 Drugs for HIV Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.4.4 Others
2.5 Drugs for HIV Sales by Application
2.5.1 Global Drugs for HIV Sale Market Share by Application (2018-2023)
2.5.2 Global Drugs for HIV Revenue and Market Share by Application (2018-2023)
2.5.3 Global Drugs for HIV Sale Price by Application (2018-2023)
3 GLOBAL DRUGS FOR HIV BY COMPANY
3.1 Global Drugs for HIV Breakdown Data by Company
3.1.1 Global Drugs for HIV Annual Sales by Company (2018-2023)
3.1.2 Global Drugs for HIV Sales Market Share by Company (2018-2023)
3.2 Global Drugs for HIV Annual Revenue by Company (2018-2023)
3.2.1 Global Drugs for HIV Revenue by Company (2018-2023)
3.2.2 Global Drugs for HIV Revenue Market Share by Company (2018-2023)
3.3 Global Drugs for HIV Sale Price by Company
3.4 Key Manufacturers Drugs for HIV Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drugs for HIV Product Location Distribution
3.4.2 Players Drugs for HIV Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DRUGS FOR HIV BY GEOGRAPHIC REGION
4.1 World Historic Drugs for HIV Market Size by Geographic Region (2018-2023)
4.1.1 Global Drugs for HIV Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Drugs for HIV Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Drugs for HIV Market Size by Country/Region (2018-2023)
4.2.1 Global Drugs for HIV Annual Sales by Country/Region (2018-2023)
4.2.2 Global Drugs for HIV Annual Revenue by Country/Region (2018-2023)
4.3 Americas Drugs for HIV Sales Growth
4.4 APAC Drugs for HIV Sales Growth
4.5 Europe Drugs for HIV Sales Growth
4.6 Middle East & Africa Drugs for HIV Sales Growth
5 AMERICAS
5.1 Americas Drugs for HIV Sales by Country
5.1.1 Americas Drugs for HIV Sales by Country (2018-2023)
5.1.2 Americas Drugs for HIV Revenue by Country (2018-2023)
5.2 Americas Drugs for HIV Sales by Type
5.3 Americas Drugs for HIV Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for HIV Sales by Region
6.1.1 APAC Drugs for HIV Sales by Region (2018-2023)
6.1.2 APAC Drugs for HIV Revenue by Region (2018-2023)
6.2 APAC Drugs for HIV Sales by Type
6.3 APAC Drugs for HIV Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Drugs for HIV by Country
7.1.1 Europe Drugs for HIV Sales by Country (2018-2023)
7.1.2 Europe Drugs for HIV Revenue by Country (2018-2023)
7.2 Europe Drugs for HIV Sales by Type
7.3 Europe Drugs for HIV Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Drugs for HIV by Country
8.1.1 Middle East & Africa Drugs for HIV Sales by Country (2018-2023)
8.1.2 Middle East & Africa Drugs for HIV Revenue by Country (2018-2023)
8.2 Middle East & Africa Drugs for HIV Sales by Type
8.3 Middle East & Africa Drugs for HIV Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drugs for HIV
10.3 Manufacturing Process Analysis of Drugs for HIV
10.4 Industry Chain Structure of Drugs for HIV
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drugs for HIV Distributors
11.3 Drugs for HIV Customer
12 WORLD FORECAST REVIEW FOR DRUGS FOR HIV BY GEOGRAPHIC REGION
12.1 Global Drugs for HIV Market Size Forecast by Region
12.1.1 Global Drugs for HIV Forecast by Region (2024-2029)
12.1.2 Global Drugs for HIV Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Drugs for HIV Forecast by Type
12.7 Global Drugs for HIV Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 ViiV Healthcare
13.1.1 ViiV Healthcare Company Information
13.1.2 ViiV Healthcare Drugs for HIV Product Portfolios and Specifications
13.1.3 ViiV Healthcare Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ViiV Healthcare Main Business Overview
13.1.5 ViiV Healthcare Latest Developments
13.2 Gilead Sciences, Inc
13.2.1 Gilead Sciences, Inc Company Information
13.2.2 Gilead Sciences, Inc Drugs for HIV Product Portfolios and Specifications
13.2.3 Gilead Sciences, Inc Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Gilead Sciences, Inc Main Business Overview
13.2.5 Gilead Sciences, Inc Latest Developments
13.3 Merck Sharp & Dohme Corp
13.3.1 Merck Sharp & Dohme Corp Company Information
13.3.2 Merck Sharp & Dohme Corp Drugs for HIV Product Portfolios and Specifications
13.3.3 Merck Sharp & Dohme Corp Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Sharp & Dohme Corp Main Business Overview
13.3.5 Merck Sharp & Dohme Corp Latest Developments
13.4 Bristol-Myers Squibb Company
13.4.1 Bristol-Myers Squibb Company Company Information
13.4.2 Bristol-Myers Squibb Company Drugs for HIV Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Company Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bristol-Myers Squibb Company Main Business Overview
13.4.5 Bristol-Myers Squibb Company Latest Developments
13.5 Janssen Pharmaceuticals, Inc.
13.5.1 Janssen Pharmaceuticals, Inc. Company Information
13.5.2 Janssen Pharmaceuticals, Inc. Drugs for HIV Product Portfolios and Specifications
13.5.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Janssen Pharmaceuticals, Inc. Main Business Overview
13.5.5 Janssen Pharmaceuticals, Inc. Latest Developments
13.6 Theratechnologies Inc.
13.6.1 Theratechnologies Inc. Company Information
13.6.2 Theratechnologies Inc. Drugs for HIV Product Portfolios and Specifications
13.6.3 Theratechnologies Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Theratechnologies Inc. Main Business Overview
13.6.5 Theratechnologies Inc. Latest Developments
13.7 Mylan Pharmaceuticals Inc.
13.7.1 Mylan Pharmaceuticals Inc. Company Information
13.7.2 Mylan Pharmaceuticals Inc. Drugs for HIV Product Portfolios and Specifications
13.7.3 Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Mylan Pharmaceuticals Inc. Main Business Overview
13.7.5 Mylan Pharmaceuticals Inc. Latest Developments
13.8 Genentech, Inc.
13.8.1 Genentech, Inc. Company Information
13.8.2 Genentech, Inc. Drugs for HIV Product Portfolios and Specifications
13.8.3 Genentech, Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Genentech, Inc. Main Business Overview
13.8.5 Genentech, Inc. Latest Developments
13.9 AbbVie Inc.
13.9.1 AbbVie Inc. Company Information
13.9.2 AbbVie Inc. Drugs for HIV Product Portfolios and Specifications
13.9.3 AbbVie Inc. Drugs for HIV Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AbbVie Inc. Main Business Overview
13.9.5 AbbVie Inc. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Drugs for HIV Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Drugs for HIV Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Major Players of Integrase Inhibitors
Table 5. Major Players of Combination HIV Medicines
Table 6. Major Players of Others
Table 7. Global Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 8. Global Drugs for HIV Sales Market Share by Type (2018-2023)
Table 9. Global Drugs for HIV Revenue by Type (2018-2023) & ($ million)
Table 10. Global Drugs for HIV Revenue Market Share by Type (2018-2023)
Table 11. Global Drugs for HIV Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 13. Global Drugs for HIV Sales Market Share by Application (2018-2023)
Table 14. Global Drugs for HIV Revenue by Application (2018-2023)
Table 15. Global Drugs for HIV Revenue Market Share by Application (2018-2023)
Table 16. Global Drugs for HIV Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Drugs for HIV Sales by Company (2018-2023) & (K Units)
Table 18. Global Drugs for HIV Sales Market Share by Company (2018-2023)
Table 19. Global Drugs for HIV Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Drugs for HIV Revenue Market Share by Company (2018-2023)
Table 21. Global Drugs for HIV Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Drugs for HIV Producing Area Distribution and Sales Area
Table 23. Players Drugs for HIV Products Offered
Table 24. Drugs for HIV Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Drugs for HIV Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Drugs for HIV Sales Market Share Geographic Region (2018-2023)
Table 29. Global Drugs for HIV Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Drugs for HIV Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Drugs for HIV Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Drugs for HIV Sales Market Share by Country/Region (2018-2023)
Table 33. Global Drugs for HIV Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Drugs for HIV Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Drugs for HIV Sales by Country (2018-2023) & (K Units)
Table 36. Americas Drugs for HIV Sales Market Share by Country (2018-2023)
Table 37. Americas Drugs for HIV Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Drugs for HIV Revenue Market Share by Country (2018-2023)
Table 39. Americas Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 40. Americas Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 41. APAC Drugs for HIV Sales by Region (2018-2023) & (K Units)
Table 42. APAC Drugs for HIV Sales Market Share by Region (2018-2023)
Table 43. APAC Drugs for HIV Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Drugs for HIV Revenue Market Share by Region (2018-2023)
Table 45. APAC Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 46. APAC Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 47. Europe Drugs for HIV Sales by Country (2018-2023) & (K Units)
Table 48. Europe Drugs for HIV Sales Market Share by Country (2018-2023)
Table 49. Europe Drugs for HIV Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Drugs for HIV Revenue Market Share by Country (2018-2023)
Table 51. Europe Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 52. Europe Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Drugs for HIV Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Drugs for HIV Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Drugs for HIV Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Drugs for HIV Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Drugs for HIV
Table 60. Key Market Challenges & Risks of Drugs for HIV
Table 61. Key Industry Trends of Drugs for HIV
Table 62. Drugs for HIV Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Drugs for HIV Distributors List
Table 65. Drugs for HIV Customer List
Table 66. Global Drugs for HIV Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Drugs for HIV Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Drugs for HIV Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Drugs for HIV Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Drugs for HIV Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Drugs for HIV Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Drugs for HIV Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Drugs for HIV Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Drugs for HIV Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Drugs for HIV Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Drugs for HIV Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Drugs for HIV Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Drugs for HIV Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Drugs for HIV Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. ViiV Healthcare Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 81. ViiV Healthcare Drugs for HIV Product Portfolios and Specifications
Table 82. ViiV Healthcare Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. ViiV Healthcare Main Business
Table 84. ViiV Healthcare Latest Developments
Table 85. Gilead Sciences, Inc Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 86. Gilead Sciences, Inc Drugs for HIV Product Portfolios and Specifications
Table 87. Gilead Sciences, Inc Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Gilead Sciences, Inc Main Business
Table 89. Gilead Sciences, Inc Latest Developments
Table 90. Merck Sharp & Dohme Corp Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 91. Merck Sharp & Dohme Corp Drugs for HIV Product Portfolios and Specifications
Table 92. Merck Sharp & Dohme Corp Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Merck Sharp & Dohme Corp Main Business
Table 94. Merck Sharp & Dohme Corp Latest Developments
Table 95. Bristol-Myers Squibb Company Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 96. Bristol-Myers Squibb Company Drugs for HIV Product Portfolios and Specifications
Table 97. Bristol-Myers Squibb Company Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Bristol-Myers Squibb Company Main Business
Table 99. Bristol-Myers Squibb Company Latest Developments
Table 100. Janssen Pharmaceuticals, Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 101. Janssen Pharmaceuticals, Inc. Drugs for HIV Product Portfolios and Specifications
Table 102. Janssen Pharmaceuticals, Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Janssen Pharmaceuticals, Inc. Main Business
Table 104. Janssen Pharmaceuticals, Inc. Latest Developments
Table 105. Theratechnologies Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 106. Theratechnologies Inc. Drugs for HIV Product Portfolios and Specifications
Table 107. Theratechnologies Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Theratechnologies Inc. Main Business
Table 109. Theratechnologies Inc. Latest Developments
Table 110. Mylan Pharmaceuticals Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 111. Mylan Pharmaceuticals Inc. Drugs for HIV Product Portfolios and Specifications
Table 112. Mylan Pharmaceuticals Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Mylan Pharmaceuticals Inc. Main Business
Table 114. Mylan Pharmaceuticals Inc. Latest Developments
Table 115. Genentech, Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 116. Genentech, Inc. Drugs for HIV Product Portfolios and Specifications
Table 117. Genentech, Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Genentech, Inc. Main Business
Table 119. Genentech, Inc. Latest Developments
Table 120. AbbVie Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 121. AbbVie Inc. Drugs for HIV Product Portfolios and Specifications
Table 122. AbbVie Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. AbbVie Inc. Main Business
Table 124. AbbVie Inc. Latest Developments
Table 1. Drugs for HIV Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Drugs for HIV Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 4. Major Players of Integrase Inhibitors
Table 5. Major Players of Combination HIV Medicines
Table 6. Major Players of Others
Table 7. Global Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 8. Global Drugs for HIV Sales Market Share by Type (2018-2023)
Table 9. Global Drugs for HIV Revenue by Type (2018-2023) & ($ million)
Table 10. Global Drugs for HIV Revenue Market Share by Type (2018-2023)
Table 11. Global Drugs for HIV Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 13. Global Drugs for HIV Sales Market Share by Application (2018-2023)
Table 14. Global Drugs for HIV Revenue by Application (2018-2023)
Table 15. Global Drugs for HIV Revenue Market Share by Application (2018-2023)
Table 16. Global Drugs for HIV Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Drugs for HIV Sales by Company (2018-2023) & (K Units)
Table 18. Global Drugs for HIV Sales Market Share by Company (2018-2023)
Table 19. Global Drugs for HIV Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Drugs for HIV Revenue Market Share by Company (2018-2023)
Table 21. Global Drugs for HIV Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Drugs for HIV Producing Area Distribution and Sales Area
Table 23. Players Drugs for HIV Products Offered
Table 24. Drugs for HIV Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Drugs for HIV Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Drugs for HIV Sales Market Share Geographic Region (2018-2023)
Table 29. Global Drugs for HIV Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Drugs for HIV Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Drugs for HIV Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Drugs for HIV Sales Market Share by Country/Region (2018-2023)
Table 33. Global Drugs for HIV Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Drugs for HIV Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Drugs for HIV Sales by Country (2018-2023) & (K Units)
Table 36. Americas Drugs for HIV Sales Market Share by Country (2018-2023)
Table 37. Americas Drugs for HIV Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Drugs for HIV Revenue Market Share by Country (2018-2023)
Table 39. Americas Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 40. Americas Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 41. APAC Drugs for HIV Sales by Region (2018-2023) & (K Units)
Table 42. APAC Drugs for HIV Sales Market Share by Region (2018-2023)
Table 43. APAC Drugs for HIV Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Drugs for HIV Revenue Market Share by Region (2018-2023)
Table 45. APAC Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 46. APAC Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 47. Europe Drugs for HIV Sales by Country (2018-2023) & (K Units)
Table 48. Europe Drugs for HIV Sales Market Share by Country (2018-2023)
Table 49. Europe Drugs for HIV Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Drugs for HIV Revenue Market Share by Country (2018-2023)
Table 51. Europe Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 52. Europe Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Drugs for HIV Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Drugs for HIV Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Drugs for HIV Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Drugs for HIV Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Drugs for HIV Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Drugs for HIV Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Drugs for HIV
Table 60. Key Market Challenges & Risks of Drugs for HIV
Table 61. Key Industry Trends of Drugs for HIV
Table 62. Drugs for HIV Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Drugs for HIV Distributors List
Table 65. Drugs for HIV Customer List
Table 66. Global Drugs for HIV Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Drugs for HIV Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Drugs for HIV Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Drugs for HIV Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Drugs for HIV Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Drugs for HIV Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Drugs for HIV Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Drugs for HIV Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Drugs for HIV Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Drugs for HIV Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Drugs for HIV Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Drugs for HIV Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Drugs for HIV Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Drugs for HIV Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. ViiV Healthcare Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 81. ViiV Healthcare Drugs for HIV Product Portfolios and Specifications
Table 82. ViiV Healthcare Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. ViiV Healthcare Main Business
Table 84. ViiV Healthcare Latest Developments
Table 85. Gilead Sciences, Inc Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 86. Gilead Sciences, Inc Drugs for HIV Product Portfolios and Specifications
Table 87. Gilead Sciences, Inc Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Gilead Sciences, Inc Main Business
Table 89. Gilead Sciences, Inc Latest Developments
Table 90. Merck Sharp & Dohme Corp Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 91. Merck Sharp & Dohme Corp Drugs for HIV Product Portfolios and Specifications
Table 92. Merck Sharp & Dohme Corp Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Merck Sharp & Dohme Corp Main Business
Table 94. Merck Sharp & Dohme Corp Latest Developments
Table 95. Bristol-Myers Squibb Company Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 96. Bristol-Myers Squibb Company Drugs for HIV Product Portfolios and Specifications
Table 97. Bristol-Myers Squibb Company Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Bristol-Myers Squibb Company Main Business
Table 99. Bristol-Myers Squibb Company Latest Developments
Table 100. Janssen Pharmaceuticals, Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 101. Janssen Pharmaceuticals, Inc. Drugs for HIV Product Portfolios and Specifications
Table 102. Janssen Pharmaceuticals, Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Janssen Pharmaceuticals, Inc. Main Business
Table 104. Janssen Pharmaceuticals, Inc. Latest Developments
Table 105. Theratechnologies Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 106. Theratechnologies Inc. Drugs for HIV Product Portfolios and Specifications
Table 107. Theratechnologies Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Theratechnologies Inc. Main Business
Table 109. Theratechnologies Inc. Latest Developments
Table 110. Mylan Pharmaceuticals Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 111. Mylan Pharmaceuticals Inc. Drugs for HIV Product Portfolios and Specifications
Table 112. Mylan Pharmaceuticals Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Mylan Pharmaceuticals Inc. Main Business
Table 114. Mylan Pharmaceuticals Inc. Latest Developments
Table 115. Genentech, Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 116. Genentech, Inc. Drugs for HIV Product Portfolios and Specifications
Table 117. Genentech, Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Genentech, Inc. Main Business
Table 119. Genentech, Inc. Latest Developments
Table 120. AbbVie Inc. Basic Information, Drugs for HIV Manufacturing Base, Sales Area and Its Competitors
Table 121. AbbVie Inc. Drugs for HIV Product Portfolios and Specifications
Table 122. AbbVie Inc. Drugs for HIV Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. AbbVie Inc. Main Business
Table 124. AbbVie Inc. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Drugs for HIV
Figure 2. Drugs for HIV Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drugs for HIV Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Drugs for HIV Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Drugs for HIV Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Figure 10. Product Picture of Integrase Inhibitors
Figure 11. Product Picture of Combination HIV Medicines
Figure 12. Product Picture of Others
Figure 13. Global Drugs for HIV Sales Market Share by Type in 2022
Figure 14. Global Drugs for HIV Revenue Market Share by Type (2018-2023)
Figure 15. Drugs for HIV Consumed in Hospital Pharmacies
Figure 16. Global Drugs for HIV Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 17. Drugs for HIV Consumed in Retail Pharmacies
Figure 18. Global Drugs for HIV Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 19. Drugs for HIV Consumed in Online Pharmacies
Figure 20. Global Drugs for HIV Market: Online Pharmacies (2018-2023) & (K Units)
Figure 21. Drugs for HIV Consumed in Others
Figure 22. Global Drugs for HIV Market: Others (2018-2023) & (K Units)
Figure 23. Global Drugs for HIV Sales Market Share by Application (2022)
Figure 24. Global Drugs for HIV Revenue Market Share by Application in 2022
Figure 25. Drugs for HIV Sales Market by Company in 2022 (K Units)
Figure 26. Global Drugs for HIV Sales Market Share by Company in 2022
Figure 27. Drugs for HIV Revenue Market by Company in 2022 ($ Million)
Figure 28. Global Drugs for HIV Revenue Market Share by Company in 2022
Figure 29. Global Drugs for HIV Sales Market Share by Geographic Region (2018-2023)
Figure 30. Global Drugs for HIV Revenue Market Share by Geographic Region in 2022
Figure 31. Americas Drugs for HIV Sales 2018-2023 (K Units)
Figure 32. Americas Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 33. APAC Drugs for HIV Sales 2018-2023 (K Units)
Figure 34. APAC Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 35. Europe Drugs for HIV Sales 2018-2023 (K Units)
Figure 36. Europe Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 37. Middle East & Africa Drugs for HIV Sales 2018-2023 (K Units)
Figure 38. Middle East & Africa Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 39. Americas Drugs for HIV Sales Market Share by Country in 2022
Figure 40. Americas Drugs for HIV Revenue Market Share by Country in 2022
Figure 41. Americas Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 42. Americas Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 43. United States Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 44. Canada Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 45. Mexico Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 46. Brazil Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 47. APAC Drugs for HIV Sales Market Share by Region in 2022
Figure 48. APAC Drugs for HIV Revenue Market Share by Regions in 2022
Figure 49. APAC Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 50. APAC Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 51. China Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 52. Japan Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 53. South Korea Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 54. Southeast Asia Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 55. India Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 56. Australia Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 57. China Taiwan Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 58. Europe Drugs for HIV Sales Market Share by Country in 2022
Figure 59. Europe Drugs for HIV Revenue Market Share by Country in 2022
Figure 60. Europe Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 61. Europe Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 62. Germany Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 63. France Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 64. UK Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 65. Italy Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 66. Russia Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 67. Middle East & Africa Drugs for HIV Sales Market Share by Country in 2022
Figure 68. Middle East & Africa Drugs for HIV Revenue Market Share by Country in 2022
Figure 69. Middle East & Africa Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 70. Middle East & Africa Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 71. Egypt Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 72. South Africa Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 73. Israel Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 74. Turkey Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 75. GCC Country Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Drugs for HIV in 2022
Figure 77. Manufacturing Process Analysis of Drugs for HIV
Figure 78. Industry Chain Structure of Drugs for HIV
Figure 79. Channels of Distribution
Figure 80. Global Drugs for HIV Sales Market Forecast by Region (2024-2029)
Figure 81. Global Drugs for HIV Revenue Market Share Forecast by Region (2024-2029)
Figure 82. Global Drugs for HIV Sales Market Share Forecast by Type (2024-2029)
Figure 83. Global Drugs for HIV Revenue Market Share Forecast by Type (2024-2029)
Figure 84. Global Drugs for HIV Sales Market Share Forecast by Application (2024-2029)
Figure 85. Global Drugs for HIV Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Drugs for HIV
Figure 2. Drugs for HIV Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drugs for HIV Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Drugs for HIV Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Drugs for HIV Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Figure 10. Product Picture of Integrase Inhibitors
Figure 11. Product Picture of Combination HIV Medicines
Figure 12. Product Picture of Others
Figure 13. Global Drugs for HIV Sales Market Share by Type in 2022
Figure 14. Global Drugs for HIV Revenue Market Share by Type (2018-2023)
Figure 15. Drugs for HIV Consumed in Hospital Pharmacies
Figure 16. Global Drugs for HIV Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 17. Drugs for HIV Consumed in Retail Pharmacies
Figure 18. Global Drugs for HIV Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 19. Drugs for HIV Consumed in Online Pharmacies
Figure 20. Global Drugs for HIV Market: Online Pharmacies (2018-2023) & (K Units)
Figure 21. Drugs for HIV Consumed in Others
Figure 22. Global Drugs for HIV Market: Others (2018-2023) & (K Units)
Figure 23. Global Drugs for HIV Sales Market Share by Application (2022)
Figure 24. Global Drugs for HIV Revenue Market Share by Application in 2022
Figure 25. Drugs for HIV Sales Market by Company in 2022 (K Units)
Figure 26. Global Drugs for HIV Sales Market Share by Company in 2022
Figure 27. Drugs for HIV Revenue Market by Company in 2022 ($ Million)
Figure 28. Global Drugs for HIV Revenue Market Share by Company in 2022
Figure 29. Global Drugs for HIV Sales Market Share by Geographic Region (2018-2023)
Figure 30. Global Drugs for HIV Revenue Market Share by Geographic Region in 2022
Figure 31. Americas Drugs for HIV Sales 2018-2023 (K Units)
Figure 32. Americas Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 33. APAC Drugs for HIV Sales 2018-2023 (K Units)
Figure 34. APAC Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 35. Europe Drugs for HIV Sales 2018-2023 (K Units)
Figure 36. Europe Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 37. Middle East & Africa Drugs for HIV Sales 2018-2023 (K Units)
Figure 38. Middle East & Africa Drugs for HIV Revenue 2018-2023 ($ Millions)
Figure 39. Americas Drugs for HIV Sales Market Share by Country in 2022
Figure 40. Americas Drugs for HIV Revenue Market Share by Country in 2022
Figure 41. Americas Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 42. Americas Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 43. United States Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 44. Canada Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 45. Mexico Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 46. Brazil Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 47. APAC Drugs for HIV Sales Market Share by Region in 2022
Figure 48. APAC Drugs for HIV Revenue Market Share by Regions in 2022
Figure 49. APAC Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 50. APAC Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 51. China Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 52. Japan Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 53. South Korea Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 54. Southeast Asia Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 55. India Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 56. Australia Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 57. China Taiwan Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 58. Europe Drugs for HIV Sales Market Share by Country in 2022
Figure 59. Europe Drugs for HIV Revenue Market Share by Country in 2022
Figure 60. Europe Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 61. Europe Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 62. Germany Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 63. France Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 64. UK Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 65. Italy Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 66. Russia Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 67. Middle East & Africa Drugs for HIV Sales Market Share by Country in 2022
Figure 68. Middle East & Africa Drugs for HIV Revenue Market Share by Country in 2022
Figure 69. Middle East & Africa Drugs for HIV Sales Market Share by Type (2018-2023)
Figure 70. Middle East & Africa Drugs for HIV Sales Market Share by Application (2018-2023)
Figure 71. Egypt Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 72. South Africa Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 73. Israel Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 74. Turkey Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 75. GCC Country Drugs for HIV Revenue Growth 2018-2023 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Drugs for HIV in 2022
Figure 77. Manufacturing Process Analysis of Drugs for HIV
Figure 78. Industry Chain Structure of Drugs for HIV
Figure 79. Channels of Distribution
Figure 80. Global Drugs for HIV Sales Market Forecast by Region (2024-2029)
Figure 81. Global Drugs for HIV Revenue Market Share Forecast by Region (2024-2029)
Figure 82. Global Drugs for HIV Sales Market Share Forecast by Type (2024-2029)
Figure 83. Global Drugs for HIV Revenue Market Share Forecast by Type (2024-2029)
Figure 84. Global Drugs for HIV Sales Market Share Forecast by Application (2024-2029)
Figure 85. Global Drugs for HIV Revenue Market Share Forecast by Application (2024-2029)
